https://mindmedicinelaw.com/briefing/psilocybin-reduces-inflammation-in-parkinson-s-u-s-phase-2-data-20261021-52523The Psychedelic Journalen2026-10-21T22:03:47.873289+00:00Psilocybin Reduces Inflammation in Parkinson’s: U.S. Phase 2 Datapsilocybin, parkinson's disease, clinical trial, inflammation, neuroprotection, phase 2, biomarkers, psychedelic research, regulatory policyhttps://mindmedicinelaw.com/briefing/mdma-assisted-therapy-and-flourishing-new-insights-from-u-s-social-anxiety-trial-20261020-52263The Psychedelic Journalen2026-10-21T15:06:52.992608+00:00MDMA-Assisted Therapy and Flourishing: New Insights from U.S. Social Anxiety Trialsmdma-assisted therapy, social anxiety disorder, self-transcendent experiences, psychological flourishing, clinical trial outcomes, wellbeing measures, regulatory implications, psychedelic research, fda guidance, trial designhttps://mindmedicinelaw.com/briefing/deep-learning-boosts-preclinical-sleep-analysis-in-psychedelic-studies-20261020-52243The Psychedelic Journalen2026-10-21T15:06:35.019841+00:00Deep Learning Boosts Preclinical Sleep Analysis in Psychedelic Studiesdeep learning, sleep stage classification, preclinical research, psychedelic drugs, EEG analysis, pharmacological interventions, neuroscience, automated annotation, translational researchhttps://mindmedicinelaw.com/briefing/optimi-health-s-mdma-production-milestone-phase-3-ptsd-trial-supply-in-focus-20261020-52190The Psychedelic Journalen2026-10-20T22:04:18.464853+00:00Optimi Health’s MDMA Production Milestone: Phase 3 PTSD Trial Supply in Focusmdma production, optimi health, phase 3 ptsd trial, gmp manufacturing, psychedelic research, clinical trial supply, health canada, fda regulation, ptsd treatment research, controlled substanceshttps://mindmedicinelaw.com/briefing/mdma-supply-milestone-optimi-health-supports-phase-3-trials-in-canada-israel-and-20261020-52026The Psychedelic Journalen2026-10-20T15:06:46.405409+00:00MDMA Supply Milestone: Optimi Health Supports Phase 3 Trials in Canada, Israel, and Australiamdma supply chain, optimi health, phase 3 clinical trials, ptsd treatment research, canada psychedelic regulation, israel maps trial, australia mdma commercial use, gmp pharmaceutical standards, psychedelic medicine infrastructurehttps://mindmedicinelaw.com/briefing/pharma-s-accelerated-push-for-ketamine-therapies-in-the-u-s-20261020-52029The Psychedelic Journalen2026-10-20T15:06:25.663973+00:00Pharma’s Accelerated Push for Ketamine Therapies in the U.S.ketamine commercialization, pharmaceutical industry, psychedelic research, FDA regulation, intellectual property, clinical trials, mental health policy, access to treatment, payer coverage, US healthcarehttps://mindmedicinelaw.com/briefing/mazatec-mushroom-medicine-ethics-and-the-western-psychedelic-renaissance-20261019-52278The Psychedelic Journalen2026-10-21T15:09:14.311272+00:00Mazatec Mushroom Medicine, Ethics, and the Western Psychedelic Renaissancemazatec mushroom medicine, psilocybin commercialization, michael pollan, indigenous rights, benefit-sharing, psychedelic industry ethics, cultural appropriation, settler colonialism, policy frameworks, reciprocityhttps://mindmedicinelaw.com/briefing/brain-connectivity-in-anhedonia-implications-for-psychedelic-trials-20261019-52245The Psychedelic Journalen2026-10-21T15:08:33.024502+00:00Brain Connectivity in Anhedonia: Implications for Psychedelic Trialsanhedonia, cortico-subcortical connectivity, psychedelic clinical trials, biomarkers, neural hierarchy, fMRI, mood disorders, mechanistic targets, transdiagnostic research, regulatory sciencehttps://mindmedicinelaw.com/briefing/lhb-remodeling-and-antidepressant-timing-ketamine-insights-for-depression-20261019-52276The Psychedelic Journalen2026-10-21T15:08:03.067260+00:00LHb Remodeling and Antidepressant Timing: Ketamine Insights for Depressionlateral habenula, ketamine, depression, spatial transcriptomics, chronic stress, rapid-acting antidepressants, clinical trial design, neurobiology of depression, psychedelic researchhttps://mindmedicinelaw.com/briefing/hhc-associated-psychosis-distinct-clinical-features-in-irish-inpatient-cohort-20261019-52246The Psychedelic Journalen2026-10-21T15:07:18.357245+00:00HHC-Associated Psychosis: Distinct Clinical Features in Irish Inpatient Cohorthhc psychosis, novel cannabinoids, cannabis-associated psychosis, psychiatric screening, toxicology, ireland mental health, public health policy, affective symptoms, thought disorder, first episode psychosishttps://mindmedicinelaw.com/briefing/dms-cp-ampars-and-aversion-resistant-alcohol-use-insights-for-addiction-neurosci-20261019-51960The Psychedelic Journalen2026-10-20T15:08:56.379453+00:00DMS CP-AMPARs and Aversion-Resistant Alcohol Use: Insights for Addiction Neurosciencedorsomedial striatum, calcium-permeable ampa receptors, aversion-resistant drinking, alcohol use disorder, synaptic plasticity, addiction neuroscience, preclinical mouse study, psychedelic research, glutamatergic signalinghttps://mindmedicinelaw.com/briefing/mdma-for-ptsd-evidence-policy-and-perception-in-the-u-s-20261019-52028The Psychedelic Journalen2026-10-20T15:08:35.171052+00:00MDMA for PTSD: Evidence, Policy, and Perception in the U.S.mdma, ptsd, fda approval, psychedelic therapy, clinical trials, drug policy, media influence, safety risks, maps pbc, dea schedulinghttps://mindmedicinelaw.com/briefing/ketamine-for-ocd-rapid-relief-short-duration-in-clinical-review-20261019-51959The Psychedelic Journalen2026-10-20T15:07:29.960608+00:00Ketamine for OCD: Rapid Relief, Short Duration in Clinical Reviewketamine, obsessive-compulsive disorder, OCD, neuroplasticity, clinical trials, NMDA receptor, adjunctive therapy, treatment-resistant OCD, psychopharmacology, regulatory policyhttps://mindmedicinelaw.com/briefing/product-specific-safety-evidence-for-cannabis-and-psilocybe-regulatory-and-clini-20261019-51947The Psychedelic Journalen2026-10-20T15:07:14.001412+00:00Product-Specific Safety Evidence for Cannabis and Psilocybe: Regulatory and Clinical Implicationsproduct-specific safety, cannabis regulation, psilocybe clinical trials, evidence extrapolation, botanical drug quality, claim-linked record, psychedelic research, regulatory standards, clinical safety, cannabinoid contenthttps://mindmedicinelaw.com/briefing/phenomenological-taxonomies-in-psychedelic-research-insights-from-yoga-v-si-ha-20261018-51916The Psychedelic Journalen2026-10-20T15:07:54.824212+00:00Phenomenological Taxonomies in Psychedelic Research: Insights from Yoga Vāsiṣṭhaphenomenological taxonomy, psychedelic research, hypnosis, yoga vāsiṣṭha, altered states, clinical trial design, fundamental peace, csst model, mystical experience, emotional regulationhttps://mindmedicinelaw.com/briefing/dea-and-iowa-approve-ayahuasca-import-for-psychedelic-church-20261017-52027The Psychedelic Journalen2026-10-20T15:05:58.730960+00:00DEA and Iowa Approve Ayahuasca Import for Psychedelic Churchayahuasca, dea approval, iowa drug policy, psychedelic church, religious exemption, entheogenic access, schedule i substances, drug import permits, rfra, psychedelic lawhttps://mindmedicinelaw.com/briefing/psilocybin-s-therapeutic-potential-depression-pain-and-inflammation-20261014-51924The Psychedelic Journalen2026-10-20T15:09:16.468462+00:00Psilocybin’s Therapeutic Potential: Depression, Pain, and Inflammationpsilocybin, depression, chronic pain, inflammation, narrative review, default mode network, clinical trial design, regulatory policy, psychedelic researchhttps://mindmedicinelaw.com/briefing/colorado-springs-police-target-unregulated-psilocybin-thc-sales-20261014-52030The Psychedelic Journalen2026-10-20T15:08:16.267324+00:00Colorado Springs Police Target Unregulated Psilocybin, THC Salescolorado springs, psilocybin enforcement, thc sales raids, psychedelic law, state vs local regulation, proposition 122, compliance risk, decriminalization, gray market